Keywords: astellas, says, advagraf, represents, step, forward, post-transplant

Astellas' says Advagraf represents step forward in post-transplant adherence

Article | 08 October 2007

The problem of non-adherence to immunosuppressive anti-rejection regimens by transplant recipients is one of the major challenges faced by health ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Go to company listing

Related Drugs

Prograf

tacrolimus

Basiliximab

Simulect

Cyclosporine

Go to drug listing